117 S253 IS: Cannabidiol and Marihuana Research Expansion Act
U.S. Senate
2021-02-04
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
1.Short title; table of contents
(a)This Act may be cited as the Cannabidiol and Marihuana Research Expansion Act
. (b)The table of contents for this Act is as follows:
Sec. 1. Short title; table of contents.
Sec. 2. Definitions.
TITLE I—Registrations for marihuana research
Sec. 101. Marihuana research applications.
Sec. 102. Research protocols.
Sec. 103. Applications to manufacture marihuana for research.
Sec. 104. Adequate and uninterrupted supply.
Sec. 105. Security requirements.
Sec. 106. Prohibition against reinstating interdisciplinary review process for non-NIH-funded researchers.
TITLE II—Development of FDA-approved drugs using cannabidiol and marihuana
Sec. 201. Medical research on cannabidiol.
Sec. 202. Registration for the commercial production and distribution of Food and Drug Administration-approved drugs.
Sec. 203. Importation of cannabidiol for research purposes.
TITLE III—Doctor-patient relationship
Sec. 301. Doctor-patient relationship.
TITLE IV—Federal research
Sec. 401. Federal research.
2.In this Act— (1)the term appropriately registered means that an individual or entity is registered under the Controlled Substances Act (21 U.S.C. 801 et seq.) to engage in the type of activity that is carried out by the individual or entity with respect to a controlled substance on the schedule that is applicable to cannabidiol or marihuana, as applicable;
(2)the term cannabidiol means— (A)the substance, cannabidiol, as derived from marihuana that has a delta-9-tetrahydrocannabinol level that is greater than 0.3 percent; and
(B)the synthetic equivalent of the substance described in subparagraph (A); (3)the terms controlled substance, dispense, distribute, manufacture, marihuana, and practitioner have the meanings given such terms in section 102 of the Controlled Substances Act (21 U.S.C. 802), as amended by this Act;
(4)the term covered institution of higher education means an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) that— (A) (i)has highest or higher research activity, as defined by the Carnegie Classification of Institutions of Higher Education; or
(ii)is an accredited medical school or an accredited school of osteopathic medicine; and (B)is appropriately registered under the Controlled Substances Act (21 U.S.C. 801 et seq.);
(5)the term drug has the meaning given the term in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(1)); (6)the term medical research for drug development means medical research that is—
(A)a preclinical study or clinical investigation conducted in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or otherwise permitted by the Department of Health and Human Services to determine the potential medical benefits of marihuana or cannabidiol as a drug; and (B)conducted by a covered institution of higher education, practitioner, or manufacturer that is appropriately registered under the Controlled Substances Act (21 U.S.C. 801 et seq.); and
(7)the term State means any State of the United States, the District of Columbia, and any territory of the United States. <enum>I</enum><header>Registrations for marihuana research</header> <section id="id8307cd5480cf4ccab451119966f08d74"><enum>101.</enum><header>Marihuana research applications</header><text display-inline="no-display-inline">Section 303(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)</external-xref>) is amended—</text>
<paragraph id="idcfcc20b652c743b5a2a5f0038f91db0f"><enum>(1)</enum><text>by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively;</text></paragraph> <paragraph id="id72f642fc1d514e66a9e46b98cc0fc7a1"><enum>(2)</enum><text>by striking <quote>(f) The Attorney General</quote> and inserting <quote>(f)(1) The Attorney General</quote>;</text></paragraph>
<paragraph id="idb3fa1a8cceef4369a96efd2e7f8b6c2b"><enum>(3)</enum><text>by striking <quote>Registration applications</quote> and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="id711d799a46e0451babaf286790e0085c" style="OLC"> <paragraph id="iddcf38342958847b2933ea019caa5fe59" indent="up1"><enum>(2)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="id19A726F2D42D46BA9A9E583006950D41"><enum>(A)</enum><text>Registration applications</text></subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></paragraph>
<paragraph id="id6cf3d6b42ecc4ac6bf61a810c37d6090"><enum>(4)</enum><text>by striking <quote>Article 7</quote> and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="id9bd837e49d6d4565880c33f741a51a17" style="OLC"> <paragraph id="id2d61165a69f94bd4af19fe103ce2df12" indent="up1"><enum>(3)</enum><text>Article 7</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph>
<paragraph id="id8453260042764ea69a76f6b05c6f2d34"><enum>(5)</enum><text>by inserting after paragraph (2)(A), as so designated, the following:</text> <quoted-block display-inline="no-display-inline" id="id91bb1779d0c34b82ac53b69668fc309c" style="OLC"> <subparagraph id="idc7072e5adc824d2fb180b0dd1c8a5c65" indent="up2"><enum>(B)</enum> <clause commented="no" display-inline="yes-display-inline" id="id528C3DF52FCD485BA734CEA890FB26C4"><enum>(i)</enum><text>The Attorney General shall register a practitioner to conduct research with marihuana if—</text>
<subclause id="id628369BC680049438947B44B19F4B0E5" indent="up1"><enum>(I)</enum><text>the applicant’s research protocol—</text> <item id="idF99ABC316D614BABB7838BB980118A6B"><enum>(aa)</enum><text>has been reviewed and allowed—</text>
<subitem id="idFD9231273425442ABDDF8E9A7AB48BF1"><enum>(AA)</enum><text>by the Secretary of Health and Human Services under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>);</text></subitem> <subitem id="idEDCC422F835B4C4F8543193A32493637"><enum>(BB)</enum><text>by the National Institutes of Health or another Federal agency that funds scientific research; or</text></subitem>
<subitem id="id06E7CCE767ED45E1BE5D01576573E3F5"><enum>(CC)</enum><text>pursuant to sections 1301.18 and 1301.32 of title 21, Code of Federal Regulations, or any successors thereto; and</text></subitem></item></subclause> <subclause id="idB40E03E7046B444188956D541A11F35E" indent="up1"><enum>(II)</enum><text>the applicant has demonstrated to the Attorney General that there are effective procedures in place to adequately safeguard against diversion of the controlled substance for legitimate medical or scientific use pursuant to section 105 of the <short-title>Cannabidiol and Marihuana Research Expansion Act</short-title>, including demonstrating that the security measures are adequate for storing the quantity of marihuana the applicant would be authorized to possess.</text></subclause></clause>
<clause id="id83746EDE53024ECDB84096C427B7786D" indent="up1"><enum>(ii)</enum><text>The Attorney General may deny an application for registration under this subparagraph only if the Attorney General determines that the issuance of the registration would be inconsistent with the public interest. In determining the public interest, the Attorney General shall consider the factors listed in—</text> <subclause id="id5D59C59214874E6BB9DD1734B17D7345"><enum>(I)</enum><text>subparagraphs (B) through (E) of paragraph (1); and</text></subclause>
<subclause id="id997D43E2959E4AB9B0F20D25F45D2EB8"><enum>(II)</enum><text>subparagraph (A) of paragraph (1), if the applicable State requires practitioners conducting research to register with a board or authority described in such subparagraph (A).</text></subclause></clause> <clause id="id164D499A4CDD47DE867F519348886DDE" indent="up1"><enum>(iii)</enum> <subclause commented="no" display-inline="yes-display-inline" id="id213B6F9916054839B306A22093D418E8"><enum>(I)</enum><text>Not later than 60 days after the date on which the Attorney General receives a complete application for registration under this subparagraph, the Attorney General shall—</text>
<item id="id4A6D7F11B6AD4825A0A031CAF1F70834" indent="up1"><enum>(aa)</enum><text>approve the application; or</text></item> <item id="idD9C65C134EE04CDE96812AAB92160789" indent="up1"><enum>(bb)</enum><text>request supplemental information.</text></item></subclause>
<subclause id="id7551F71D59424B2AA75BB11BF4D0CD55" indent="up1"><enum>(II)</enum><text>For purposes of subclause (I), an application shall be deemed complete when the applicant has submitted documentation showing that the requirements under clause (i) are satisfied.</text></subclause></clause> <clause id="idEAE1A3612D874F2A8AE73D50108EBD8D" indent="up1"><enum>(iv)</enum><text>Not later than 30 days after the date on which the Attorney General receives supplemental information as described in clause (iii)(I)(bb) in connection with an application described in this subparagraph, the Attorney General shall approve or deny the application.</text></clause>
<clause id="id5EAFED318596434F83A1A6137BD76A5C" indent="up1"><enum>(v)</enum><text>If an application described in this subparagraph is denied, the Attorney General shall provide a written explanation of the basis of denial to the applicant.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> <section id="id70e49aa692de468b9afaf0b5b3ac641c"><enum>102.</enum><header>Research protocols</header> <subsection id="id2694233CA48C489C8BD0C6AD89758661"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Paragraph (2)(B) of section 303(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)</external-xref>), as amended by section 101 of this Act, is further amended by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="ide2ac247acef344da8285cf0e8aa580c6" style="OLC">
<clause id="id80654c31d1f444729719d8556ca5e329" indent="up3"><enum>(vi)</enum>
<subclause commented="no" display-inline="yes-display-inline" id="idE1427C9757D9412FA7EB61956A917F69"><enum>(I)</enum><text>If the Attorney General grants an application for registration under clause (i), the registrant may amend or supplement the research protocol without reapplying if the registrant does not change—</text> <item id="idd8ddffec32a34c2ea0abcbb5ab42c92c" indent="up1"><enum>(aa)</enum><text>the quantity or type of drug;</text></item>
<item id="id487ed7f48a434ff8bc3cd1825cfbed20" indent="up1"><enum>(bb)</enum><text>the source of the drug; or</text></item> <item id="idcc700d98631e44579536f50f3b4f47f9" indent="up1"><enum>(cc)</enum><text>the conditions under which the drug is stored, tracked, or administered.</text></item></subclause>
<subclause id="id6fb15cfe1fd9485db8a2a2c86f0d44f6" indent="up1"><enum>(II)</enum>
<item commented="no" display-inline="yes-display-inline" id="id6D9BB59A11E4439B80F9F39481F3BBC6"><enum>(aa)</enum><text>If a registrant under clause (i) seeks to change the type of drug, the source of the drug, or conditions under which the drug is stored, tracked, or administered, the registrant shall notify the Attorney General via registered mail, or an electronic means permitted by the Attorney General, not later than 30 days before implementing an amended or supplemental research protocol.</text></item> <item id="id74135125f3c04ebc9c652fd6ac20311c" indent="up1"><enum>(bb)</enum><text>A registrant may proceed with an amended or supplemental research protocol described in item (aa) if the Attorney General does not explicitly object during the 30-day period beginning on the date on which the Attorney General receives the notice under item (aa).</text></item>
<item id="id5d0b548a6e1b4af79ce09870d30e8332" indent="up1"><enum>(cc)</enum><text>The Attorney General may only object to an amended or supplemental research protocol under this subclause if additional security measures are needed to safeguard against diversion or abuse.</text></item> <item id="id2650A64184564A22A01ADDD8F0AB59DB" indent="up1"><enum>(dd)</enum><text>If a registrant under clause (i) seeks to address additional security measures identified by the Attorney General under item (cc), the registrant shall notify the Attorney General via registered mail, or an electronic means permitted by the Attorney General, not later than 30 days before implementing an amended or supplemental research protocol.</text></item>
<item id="id27563D3089074FFD97B23129DB3A9348" indent="up1"><enum>(ee)</enum><text>A registrant may proceed with an amended or supplemental research protocol described in item (dd) if the Attorney General does not explicitly object during the 30-day period beginning on the date on which the Attorney General receives the notice under item (dd).</text></item></subclause> <subclause id="id659275daaf694bf781cdeacaedb39d42" indent="up1"><enum>(III)</enum> <item commented="no" display-inline="yes-display-inline" id="id675d5a764d67454da5018d85643301b5"><enum>(aa)</enum><text>If a registrant under clause (i) seeks to change the quantity of marihuana needed for research and the change in quantity does not impact the factors described in item (bb) or (cc) of subclause (I) of this clause, the registrant shall notify the Attorney General via registered mail or using an electronic means permitted by the Attorney General.</text></item>
<item id="id2a99a4d10456426b84195c4860773055" indent="up1"><enum>(bb)</enum><text>A notification under item (aa) shall include—</text> <subitem id="ida98d19b348ca4754aa4f1d999c2a4412"><enum>(AA)</enum><text>the Drug Enforcement Administration registration number of the registrant;</text></subitem>
<subitem id="idd7fe508d9538438a950b9aad01e6f522"><enum>(BB)</enum><text>the quantity of marihuana already obtained;</text></subitem> <subitem id="id0d47d35b2f3642e99e20218574a43e7e"><enum>(CC)</enum><text>the quantity of additional marihuana needed to complete the research; and</text></subitem>
<subitem id="idf5e249d6970d4e708f2588dbf1c387c8"><enum>(DD)</enum><text>an attestation that the change in quantity does not impact the source of the drug or the conditions under which the drug is stored, tracked, or administered.</text></subitem></item> <item id="id6863197cf911461f8860b7341488cc74" indent="up1"><enum>(cc)</enum><text>The Attorney General shall ensure that—</text>
<subitem id="id4f0fa7f3531f4d408d921e4b6431cdf6"><enum>(AA)</enum><text>any registered mail return receipt with respect to a notification under item (aa) is submitted for delivery to the registrant providing the notification not later than 3 days after receipt of the notification by the Attorney General; and</text></subitem> <subitem id="ida769c96d5af548f0996471972b178fa6"><enum>(BB)</enum><text>notice of receipt of a notification using an electronic means permitted under item (aa) is provided to the registrant providing the notification not later than 3 days after receipt of the notification by the Attorney General.</text></subitem></item>
<item id="id9edbbdf2e13046dea9f28ae5c3493657" indent="up1"><enum>(dd)</enum>
<subitem commented="no" display-inline="yes-display-inline" id="id29622844d5c44eb0b22c437214042bf4"><enum>(AA)</enum><text>On and after the date described in subitem (BB), a registrant that submits a notification in accordance with item (aa) may proceed with the research as if the change in quantity has been approved on such date, unless the Attorney General notifies the registrant of an objection described in item (ee).</text></subitem> <subitem id="id35b41e30f64545d6b1fa2ce24ca763aa" indent="up1"><enum>(BB)</enum><text>The date described in this subitem is the date on which a registrant submitting a notification under item (aa) receives the registered mail return receipt with respect to the notification or the date on which the registrant receives notice that the notification using an electronic means permitted under item (aa) was received by the Attorney General, as the case may be.</text></subitem></item>
<item id="id8d3436f54cff4955a1ffe2e3990a6d87" indent="up1"><enum>(ee)</enum><text>A notification submitted under item (aa) shall be deemed to be approved unless the Attorney General, not later than 10 days after receiving the notification, explicitly objects based on a finding that the change in quantity—</text> <subitem id="id530886d2c12340eb98a68034e74b49ac"><enum>(AA)</enum><text>does impact the source of the drug or the conditions under which the drug is stored, tracked, or administered; or</text></subitem>
<subitem id="iddab50153f34843379b5b5da744b94bf1"><enum>(BB)</enum><text>necessitates that the registrant implement additional security measures to safeguard against diversion or abuse.</text></subitem></item></subclause> <subclause id="id99ca2767219f413497bc8316fe58cbf1" indent="up1"><enum>(IV)</enum><text>Nothing in this clause shall limit the authority of the Secretary of Health and Human Services over requirements related to research protocols, including changes in—</text>
<item id="id0a45b72ccb994d149519a8f9d4e283c0"><enum>(aa)</enum><text>the method of administration of marihuana;</text></item> <item id="id41508e966b3d44f5a77a3af78583615b"><enum>(bb)</enum><text>the dosing of marihuana; and</text></item>
<item id="id3ff8adc462c140e3a375301dfd4edca4"><enum>(cc)</enum><text>the number of individuals or patients involved in research.</text></item></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="idE96B179571764C3A959B123D7D0B4141"><enum>(b)</enum><header>Regulations</header><text>Not later than 1 year after the date of enactment of this Act, the Attorney General shall promulgate regulations to carry out the amendment made by this section.</text></subsection></section>
<section id="ide18b5e4ca3b9404d901585c01be58fc0"><enum>103.</enum><header>Applications to manufacture marihuana for research</header>
<subsection id="idF7010B31B1A54EF8BF7B01CA1800F70A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended—</text> <paragraph id="id0b8e0b8ae9cf4738b2daf190a89132ba"><enum>(1)</enum><text>by redesignating subsections (c) through (k) as subsections (d) through (l), respectively;</text></paragraph>
<paragraph id="id768e7ee05f1c43cea7002fd0a749e3c6"><enum>(2)</enum><text>by inserting after subsection (b) the following:</text> <quoted-block display-inline="no-display-inline" id="id1c754d7b02904001ad31f627de62292c" style="OLC"> <subsection id="id9345ea0ffce845aaadcc609d7abd83b4"><enum>(c)</enum> <paragraph commented="no" display-inline="yes-display-inline" id="idF095D4E8832C45709DA554C035A7C070"><enum>(1)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="id7476669120134449AD758F60A3780829"><enum>(A)</enum><text>As it relates to applications to manufacture marihuana for research purposes, if the Attorney General places a notice in the Federal Register to increase the number of entities registered under this Act to manufacture marihuana to supply appropriately registered researchers in the United States, the Attorney General shall, not later than 60 days after the date on which the Attorney General receives a completed application—</text>
<clause id="id4AC2DC95FCBE4A77BB3BF19F694581ED" indent="up2"><enum>(i)</enum><text>approve the application; or</text></clause> <clause id="idACF055F771F041DAB89C78CFD958732B" indent="up2"><enum>(ii)</enum><text>request supplemental information.</text></clause></subparagraph>
<subparagraph id="idED5348FE9A8B4022BD9B08D8363AF6DD" indent="up2"><enum>(B)</enum><text>For purposes of subparagraph (A), an application shall be deemed complete when the applicant has submitted documentation showing each of the following:</text> <clause id="id271DAD45A39A4CCFA975D59D34E27431"><enum>(i)</enum><text>The requirements designated in the notice in the Federal Register are satisfied.</text></clause>
<clause id="id29260f5ebf054aa9a82dd7242758a27e"><enum>(ii)</enum><text>The requirements under this Act are satisfied.</text></clause> <clause id="id0f97de73deb44a4da8a729214f6c086e"><enum>(iii)</enum><text>The applicant will limit the transfer and sale of any marihuana manufactured under this subsection—</text>
<subclause id="id1b0b838bb6da4977b95bb4ccbcabb9e6"><enum>(I)</enum><text>to researchers who are registered under this Act to conduct research with controlled substances in schedule I; and</text></subclause> <subclause id="idf7be1672415b48d0bb6a058fea293348"><enum>(II)</enum><text>for purposes of use in preclinical research or in a clinical investigation pursuant to an investigational new drug exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>).</text></subclause></clause>
<clause id="id978979f47dcd44d586c5f60a9ecf0c8e"><enum>(iv)</enum><text>The applicant will transfer or sell any marihuana manufactured under this subsection only with prior, written consent for the transfer or sale by the Attorney General.</text></clause> <clause id="id2daa51a26b834696a3bfc45f31b00dd4"><enum>(v)</enum><text>The applicant has completed the application and review process under subsection (a) for the bulk manufacture of controlled substances in schedule I.</text></clause>
<clause id="idccc5fbcf3fd8421a926c288277f6e7b9"><enum>(vi)</enum><text>The applicant has established and begun operation of a process for storage and handling of controlled substances in schedule I, including for inventory control and monitoring security in accordance with section 105 of the <short-title>Cannabidiol and Marihuana Research Expansion Act</short-title>.</text></clause> <clause id="id137179c2a7f34ad0982fbed3b874fcbf"><enum>(vii)</enum><text>The applicant is licensed by each State in which the applicant will conduct operations under this subsection, to manufacture marihuana, if that State requires such a license.</text></clause></subparagraph>
<subparagraph commented="no" display-inline="no-display-inline" id="id6A0F4848E5B34F6C894C67629C6E631B" indent="up2"><enum>(C)</enum><text display-inline="yes-display-inline">Not later than 30 days after the date on which the Attorney General receives supplemental information requested under subparagraph (A)(ii) with respect to an application, the Attorney General shall approve or deny the application.</text></subparagraph></paragraph> <paragraph id="id006BB30B85674AF891CB7DD0E9697676" indent="up1"><enum>(2)</enum><text>If an application described in this subsection is denied, the Attorney General shall provide a written explanation of the basis of denial to the applicant.</text></paragraph></subsection><after-quoted-block>; </after-quoted-block></quoted-block></paragraph>
<paragraph id="idF2099281C5EB4F78B46ADC023FEF49D1"><enum>(3)</enum><text>in subsection (h)(2), as so redesignated, by striking <quote>subsection (f)</quote> each place it appears and inserting <quote>subsection (g)</quote>;</text></paragraph> <paragraph id="idFD9D7487F4CC4DB39220C35F4ADEEA06"><enum>(4)</enum><text>in subsection (j)(1), as so redesignated, by striking <quote>subsection (d)</quote> and inserting <quote>subsection (e)</quote>; and</text></paragraph>
<paragraph id="idE7FBAEB3FEF54BBF8C087FB2CAF9FBDC"><enum>(5)</enum><text>in subsection (k), as so redesignated, by striking <quote>subsection (f)</quote> each place it appears and inserting <quote>subsection (g)</quote>.</text></paragraph></subsection> <subsection id="id35A7D28C5B3C4A31998D8134ED5DE788"><enum>(b)</enum><header>Technical and conforming amendments</header> <paragraph id="idEE08B672F7034840A1C653065270B0F6"><enum>(1)</enum><text>The Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801</external-xref> et seq.) is amended—</text>
<subparagraph id="idBDAE89ED1D7C4E718BC9DBD69EA98810"><enum>(A)</enum><text>in section 102 (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>)—</text> <clause id="id0c03e3fc993b45b9ac41185f0d635d34"><enum>(i)</enum><text>in paragraph (16)(B)—</text>
<subclause id="id6eb670ff6aab4b07ba5e4aa033531596"><enum>(I)</enum><text>in clause (i), by striking <quote>or</quote> at the end;</text></subclause> <subclause id="id30a4029ece4c4976800c385f9b1bab0b"><enum>(II)</enum><text>by redesignating clause (ii) as (iii); and</text></subclause>
<subclause id="id17b27424293741c887b179ea7602dfc2"><enum>(III)</enum><text>by inserting after clause (i) the following:</text> <quoted-block display-inline="no-display-inline" id="idE0AE42C142BF455F9DCF0246B2823ECE" style="OLC"> <clause id="idfc78f4198c7b4546990f72a1bd11eab6" indent="up1"><enum>(ii)</enum><text>the synthetic equivalent of hemp-derived cannabidiol that contains less than 0.3 percent tetrahydrocannabinol; or</text></clause><after-quoted-block>; </after-quoted-block></quoted-block></subclause></clause>
<clause id="idF132FDE2EE7249EEAFCC52B45578F14C"><enum>(ii)</enum><text>in paragraph (52)(B)—</text> <subclause id="id0527DFF5AAF6461E89A39F59067C4ECA"><enum>(I)</enum><text>by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>; and</text></subclause>
<subclause id="id898A9621F8B14EE08FF1225BF754CB54"><enum>(II)</enum><text>in clause (i), by striking <quote>(d), or (e)</quote> and inserting <quote>(e), or (f)</quote>; and</text></subclause></clause> <clause id="id3154BE27E70A469187489662904F693D"><enum>(iii)</enum><text>in paragraph (54), by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>;</text></clause></subparagraph>
<subparagraph id="id8BDD61174C014D0F8991CD9180034E03"><enum>(B)</enum><text>in section 302(g)(5)(A)(iii)(I)(bb) (21 U.S.C. 822(g)(5)(A)(iii)(I)(bb)), by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>; </text></subparagraph> <subparagraph id="id90C385C0D3C14A9B80F0CD8DAE4CF26E"><enum>(C)</enum><text>in section 304 (<external-xref legal-doc="usc" parsable-cite="usc/21/824">21 U.S.C. 824</external-xref>), by striking <quote>303(g)(1)</quote> each place it appears and inserting <quote>303(h)(1)</quote>;</text></subparagraph>
<subparagraph id="id6225C4AF7D554534A5CAFD823127ACB9"><enum>(D)</enum><text>in section 307(d)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/827">21 U.S.C. 827(d)(2)</external-xref>), by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>;</text></subparagraph> <subparagraph id="id02D30B59166F4086A87F4E2C7959C8C6"><enum>(E)</enum><text>in section 309A(a)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/829a">21 U.S.C. 829a(a)(2)</external-xref>), in the matter preceding subparagraph (A), by striking <quote>303(g)(2)</quote> and inserting <quote>303(h)(2)</quote>; </text></subparagraph>
<subparagraph id="id0D706750A45A45AEA0582BACE3DCF252"><enum>(F)</enum><text>in section 311(h) (<external-xref legal-doc="usc" parsable-cite="usc/21/831">21 U.S.C. 831(h)</external-xref>), by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>;</text></subparagraph> <subparagraph id="id02D4692FAC824C4BB794AB9D7D2D4CAE"><enum>(G)</enum><text>in section 401(h)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841(h)(2)</external-xref>), by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>;</text></subparagraph>
<subparagraph id="id6D728FE398FC4E33860A5A26ABC7F31A"><enum>(H)</enum><text>in section 403(c)(2)(B) (<external-xref legal-doc="usc" parsable-cite="usc/21/843">21 U.S.C. 843(c)(2)(B)</external-xref>), by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>; and</text></subparagraph> <subparagraph id="id8212AEF026D14E319774E2B8C7CF9226"><enum>(I)</enum><text>in section 512(c)(1) (<external-xref legal-doc="usc" parsable-cite="usc/21/882">21 U.S.C. 882(c)(1)</external-xref>) by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>.</text></subparagraph></paragraph>
<paragraph id="idE585FF636F924A21B2B742B8F7EE6598"><enum>(2)</enum><text>Section 1008(c) of the Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/958">21 U.S.C. 958(c)</external-xref>) is amended—</text> <subparagraph id="id6C3D5892B52345C2ACFEDBFF4034A285"><enum>(A)</enum><text>in paragraph (1), by striking <quote>303(d)</quote> and inserting <quote>303(e)</quote>; and</text></subparagraph>
<subparagraph id="idBCAD6DB294E24D598F812E68D4BC4199"><enum>(B)</enum><text>in paragraph (2)(B), by striking <quote>303(h)</quote> and inserting <quote>303(i)</quote>.</text></subparagraph></paragraph> <paragraph id="id4E61456F526341C1A491B3BF9A0398C6"><enum>(3)</enum><text>Title V of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290aa">42 U.S.C. 290aa</external-xref> et seq.) is amended—</text>
<subparagraph id="id743BA0220F7147C78D2BD631F99DC9EF"><enum>(A)</enum><text>in section 520E–4(c) (42 U.S.C. 290bb–36d(c)), by striking <quote>303(g)(2)(B)</quote> and inserting <quote>303(h)(2)(B)</quote>; and</text></subparagraph> <subparagraph id="idC0506D9F2C0040D2809B169CF338C81E"><enum>(B)</enum><text>in section 544(a)(3) (<external-xref legal-doc="usc" parsable-cite="usc/42/290dd-3">42 U.S.C. 290dd–3(a)(3)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>.</text></subparagraph></paragraph>
<paragraph id="id3D45AF538CA64288971442FEA96A06E5"><enum>(4)</enum><text>Title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395</external-xref> et seq.) is amended—</text> <subparagraph id="id39B5D2DAB7F54BFE910CA87615F19499"><enum>(A)</enum><text>in section 1833(bb)(3)(B) (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(bb)(3)(B)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; </text></subparagraph>
<subparagraph id="idBE023FD41B8B4C968B393A4FA7C3999B"><enum>(B)</enum><text>in section 1834(o)(3)(C)(ii) (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(o)(3)(C)(ii)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; and</text></subparagraph> <subparagraph id="id02A87A2F6718452491F2058AEE84A326"><enum>(C)</enum><text>in section 1866F(c)(3)(C) (<external-xref legal-doc="usc" parsable-cite="usc/42/1395cc-6">42 U.S.C. 1395cc–6(c)(3)(C)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>. </text></subparagraph></paragraph>
<paragraph id="id43DB0F0A693740229D2B27EDA5A82E9E"><enum>(5)</enum><text>Section 1903(aa)(2)(C)(ii) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396b">42 U.S.C. 1396b(aa)(2)(C)(ii)</external-xref>) is amended by striking <quote>303(g)</quote> each place it appears and inserting <quote>303(h)</quote>. </text></paragraph></subsection></section> <section id="id763c6e935b8a478691023637565af835"><enum>104.</enum><header>Adequate and uninterrupted supply</header><text display-inline="no-display-inline">On an annual basis, the Attorney General shall assess whether there is an adequate and uninterrupted supply of marihuana, including of specific strains, for research purposes.</text></section>
<section id="id8e61efea72854b0cad2f14eb04cfd512"><enum>105.</enum><header>Security requirements</header>
<subsection id="id28856c1a55414c5ba20b9484f262a4ee"><enum>(a)</enum><header>In general</header><text>An individual or entity engaged in researching marihuana or its components shall store it in a securely locked, substantially constructed cabinet.</text></subsection> <subsection id="id435f8f29fe604cfd9eee9d769289d9bc"><enum>(b)</enum><header>Requirements for other measures</header><text>Any other security measures required by the Attorney General to safeguard against diversion shall be consistent with those required for practitioners conducting research on other controlled substances in schedules I and II in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>) that have a similar risk of diversion and abuse.</text></subsection></section>
<section id="idf11fab7bb81240f79050c96260b1744c"><enum>106.</enum><header>Prohibition against reinstating interdisciplinary review process for non-NIH-funded researchers</header><text display-inline="no-display-inline">The Secretary of Health and Human Services may not—</text> <paragraph id="id604dd05ecb904ad19a21fc736905df91"><enum>(1)</enum><text>reinstate the Public Health Service interdisciplinary review process described in the guidance entitled <quote>Guidance on Procedures for the Provision of Marijuana for Medical Research</quote> (issued on May 21, 1999); or</text></paragraph>
<paragraph id="id7df49a5425bb480fb49532c3043ccdb9"><enum>(2)</enum><text>require another review of scientific protocols that is applicable only to research on marihuana or its components.</text></paragraph></section> <enum>II</enum><header>Development of FDA-approved drugs using cannabidiol and marihuana</header> <section id="idE3159A2D32DA4C81B1B228368B78CCFA"><enum>201.</enum><header>Medical research on cannabidiol</header><text display-inline="no-display-inline">Notwithstanding any provision of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801</external-xref> et seq.), the Safe and Drug-Free Schools and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/20/7101">20 U.S.C. 7101</external-xref> et seq.), <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/41/81">chapter 81</external-xref> of title 41, United States Code, or any other Federal law, an appropriately registered covered institution of higher education, a practitioner, or a manufacturer may manufacture, distribute, dispense, or possess marihuana or cannabidiol if the marihuana or cannabidiol is manufactured, distributed, dispensed, or possessed, respectively, for purposes of medical research for drug development or subsequent commercial production in accordance with section 202.</text></section>
<section id="id701e46c972624062893a1e78271895d5"><enum>202.</enum><header>Registration for the commercial production and distribution of Food and Drug Administration-approved drugs</header><text display-inline="no-display-inline">The Attorney General shall register an applicant to manufacture or distribute cannabidiol or marihuana for the purpose of commercial production of a drug containing or derived from marihuana that is approved by the Secretary of Health and Human Services under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), in accordance with the applicable requirements under subsection (a) or (b) of section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>).</text></section> <section commented="no" id="id4986074B000A487A82F5B75A099BA19D"><enum>203.</enum><header>Importation of cannabidiol for research purposes</header><text display-inline="no-display-inline">The Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/951">21 U.S.C. 951</external-xref> et seq.) is amended—</text>
<paragraph commented="no" id="id6BEC9E86ADB540A38DAC2CDB6BC8FD43"><enum>(1)</enum><text display-inline="yes-display-inline">in section 1002(a) (<external-xref legal-doc="usc" parsable-cite="usc/21/952">21 U.S.C. 952(a)</external-xref>)—</text> <subparagraph commented="no" id="id0AE198C907A44A6289D414CDA44CD8ED"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>and</quote> at the end;</text></subparagraph>
<subparagraph commented="no" id="id217C4B7454374800AF0003C6EA11D0AE"><enum>(B)</enum><text>in paragraph (2)(C), by inserting <quote>and</quote> after <quote>uses,</quote>; and</text></subparagraph> <subparagraph commented="no" id="id18F3FC899C09472BAE03D85EA2C27D43"><enum>(C)</enum><text>inserting before the undesignated matter following paragraph (2)(C) the following:</text>
<quoted-block display-inline="no-display-inline" id="idf127ef644af24531b99b40c438649d6a" style="OLC">
<paragraph commented="no" id="idcc6ed5b8515a42b9ad605b88a5b4e72b"><enum>(3)</enum><text>such amounts of marihuana or cannabidiol (as defined in section 2 of the <short-title>Cannabidiol and Marihuana Research Expansion Act</short-title>) as are—</text> <subparagraph commented="no" id="id2F53E9ACA7C7496EAAC32498F5D0980E"><enum>(A)</enum><text>approved for medical research for drug development (as such terms are defined in section 2 of the <short-title>Cannabidiol and Marihuana Research Expansion Act</short-title>), or</text></subparagraph>
<subparagraph commented="no" id="id72F2964436E24E04AB14F9EF6C777753"><enum>(B)</enum><text>necessary for registered manufacturers to manufacture drugs containing marihuana or cannabidiol that have been approved for use by the Commissioner of Food and Drugs under the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301</external-xref> et seq.),</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph> <paragraph commented="no" id="idD2563F4405A646859A4664A540AAF573"><enum>(2)</enum><text>in section 1007 (<external-xref legal-doc="usc" parsable-cite="usc/21/957">21 U.S.C. 957</external-xref>), by amending subsection (a) to read as follows:</text>
<quoted-block display-inline="no-display-inline" id="idBFF8FDA8AD584569B74B27E12196F48D" style="OLC">
<subsection id="id46B4009EACBF4CD393EA44F48981B089"><enum>(a)</enum>
<paragraph commented="no" display-inline="yes-display-inline" id="idB961E9F446C645B3A3E3751D1B82162C"><enum>(1)</enum><text>Except as provided in paragraph (2), no person may—</text> <subparagraph id="IDEA5A457ACEF34CB685084EBF60551F46" indent="up1"><enum>(A)</enum><text>import into the customs territory of the United States from any place outside thereof (but within the United States), or import into the United States from any place outside thereof, any controlled substance or list I chemical, or</text></subparagraph>
<subparagraph id="IDB5E9977C43164EBF886C70951BAC100A" indent="up1"><enum>(B)</enum><text>export from the United States any controlled substance or list I chemical,</text></subparagraph><continuation-text continuation-text-level="paragraph" indent="subsection">unless there is in effect with respect to such person a registration issued by the Attorney General under section 1008, or unless such person is exempt from registration under subsection (b).</continuation-text></paragraph> <paragraph id="id02BD82867E5544B2A8425AA7DE101FB6" indent="subsection"><enum>(2)</enum><text>Paragraph (1) shall not apply to the import or export of marihuana or cannabidiol (as defined in section 2 of the <short-title>Cannabidiol and Marihuana Research Expansion Act</short-title>) that has been approved for—</text>
<subparagraph id="id2AC02C885EE24FB2B6DD462F6D5D9123" indent="paragraph"><enum>(A)</enum><text>medical research for drug development authorized under section 201 of the <short-title>Cannabidiol and Marihuana Research Expansion Act</short-title>; or</text></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="id4293CB698A12487AA7C2AA7ACC8F080C" indent="paragraph"><enum>(B)</enum><text display-inline="yes-display-inline">use by registered manufacturers to manufacture drugs containing marihuana or cannabidiol that have been approved for use by the Commissioner of Food and Drugs under the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301</external-xref> et seq.).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section>
<enum>III</enum><header>Doctor-patient relationship</header>
<section id="id2684313A4501482DB8CD4B9ACC08682A"><enum>301.</enum><header>Doctor-patient relationship</header><text display-inline="no-display-inline">It shall not be a violation of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801</external-xref> et seq.) for a State-licensed physician to discuss—</text> <paragraph id="id1DE85E6C17154F31A509861CA1F20AC3"><enum>(1)</enum><text display-inline="yes-display-inline">the currently known potential harms and benefits of marihuana derivatives, including cannabidiol, as a treatment with the legal guardian of the patient of the physician if the patient is a child; or</text></paragraph>
<paragraph id="id1E7D0635961148FF8F16A4EF99A5499A"><enum>(2)</enum><text>the currently known potential harms and benefits of marihuana and marihuana derivatives, including cannabidiol, as a treatment with the patient or the legal guardian of the patient of the physician if the patient is a legal adult.</text></paragraph></section> <enum>IV</enum><header>Federal research</header> <section id="idab7f0c70065b4f6f8c249ada88d0148d"><enum>401.</enum><header>Federal research</header> <subsection id="id534FECA8D8AB43268DB42A51ED9C05CA"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, in coordination with the Director of the National Institutes of Health and the heads of other relevant Federal agencies, shall submit to the Caucus on International Narcotics Control, the Committee on the Judiciary, and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce and the Committee on the Judiciary of the House of Representatives a report on—</text>
<paragraph id="idce8ee7b7cc7e4cd8a1fb883fe254e0f9"><enum>(1)</enum><text>the potential therapeutic effects of cannabidiol or marihuana on serious medical conditions, including intractable epilepsy;</text></paragraph> <paragraph id="idf32bd656855b4a21994f6cda2defb005"><enum>(2)</enum><text>the potential effects of marihuana, including—</text>
<subparagraph id="idf599c8deac054c6da8c66b8bbd1acd67"><enum>(A)</enum><text>the effect of increasing delta-9-tetrahydrocannabinol levels on the human body and developing adolescent brains; and</text></subparagraph> <subparagraph id="idf8c63408609942698169bd39acee0122"><enum>(B)</enum><text>the effect of various delta-9-tetrahydrocannabinol levels on cognitive abilities, such as those that are required to operate motor vehicles or other heavy equipment; and</text></subparagraph></paragraph>
<paragraph id="id68c344da7ad2433ebc847dca5dc87ab9"><enum>(3)</enum><text>the barriers associated with researching marihuana or cannabidiol in States that have legalized the use of such substances, which shall include—</text> <subparagraph id="idabc610192c3343d0b2860e98fa376766"><enum>(A)</enum><text>recommendations as to how such barriers might be overcome, including whether public-private partnerships or Federal-State research partnerships may or should be implemented to provide researchers with access to additional strains of marihuana and cannabidiol; and</text></subparagraph>
<subparagraph id="idba4612fb6ec64cc2a126134c7e11ede4"><enum>(B)</enum><text>recommendations as to what safeguards must be in place to verify—</text> <clause id="idB11D3EA751B44343BA4680365947A91A"><enum>(i)</enum><text>the levels of tetrahydrocannabinol, cannabidiol, or other cannabinoids contained in products obtained from such States is accurate; and</text></clause>
<clause id="id998B3698B70E49E388C9F4FA2955F541"><enum>(ii)</enum><text>that such products do not contain harmful or toxic components.</text></clause></subparagraph></paragraph></subsection> <subsection id="idde0a66f89c404d72b469c407faeea9d5" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header>Activities</header><text>To the extent practicable, the Secretary of Health and Human Services, either directly or through awarding grants, contacts, or cooperative agreements, shall expand and coordinate the activities of the National Institutes of Health and other relevant Federal agencies to better determine the effects of cannabidiol and marihuana, as outlined in the report submitted under paragraphs (1) and (2) of subsection (a).</text></subsection></section>